Malaria has been a major global health problem of humans through history and is a leading
cause of death and disease across many tropical and subtropical countries. Over the last …

Progress made in malaria control during the past decade has prompted increasing global
dialogue on malaria elimination and eradication. The product development pipeline for …

Virus-like particles (VLPs) are non-infectious self-assembling nanoparticles, useful in
medicine and nanotechnology. Their repetitive molecularly-defined architecture is attractive …

Nanoscale organization is crucial to stimulating an immune response. Using self-
assembling proteins as multimerization platforms provides a safe and immunogenic system …

Malaria is a vector-borne disease of global importance, with the vast majority of its life-
threatening cases caused by infection with Plasmodium falciparum parasites. Repeated …

Plasmodium parasites are the causative agent of human malaria, and the development of a
highly effective vaccine against infection, disease and transmission remains a key priority. It …

Malaria transmission-blocking vaccines (TBVs) target the development of Plasmodium
parasites within the mosquito, with the aim of preventing malaria transmission from one …

Development of effective malaria vaccines requires delivery platforms to enhance the
immunogenicity and efficacy of the target antigens. This is particularly challenging for …

The world has made tremendous progress in the fight against malaria in the past 15 years.
According to the World Malaria Report, malaria case incidence was reduced by 41 percent …

Transmission-blocking vaccines (TBV) target the sexual-stages of the malaria parasite in the
mosquito midgut and are widely considered to be an essential tool for malaria elimination …